MABXIENCE RESEARCH SL.
Location
Madrid
Founded
2015-12-23
Website
Risk Signals
16 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MABXIENCE RESEARCH SL.
Live alerts from global media, monitored by Business Radar
2025-03-04 (businesswire.com)
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Read more
2023-12-25 (indiatimes.com)
Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience
Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience for Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of America.
Read more
(batimes.com.ar)
Pride and emotion run high inside lab set to produce Covid-19 vaccine
Work has already began at Argentina's mAbxience lab, where they're gearing up to begin producing millions of doses of a vaccine against Covid-19.
Read more